Equities analysts predict that Acorda Therapeutics Inc (NASDAQ:ACOR) will post sales of $126.87 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Acorda Therapeutics’ earnings, with the lowest sales estimate coming in at $116.30 million and the highest estimate coming in at $147.60 million. Acorda Therapeutics posted sales of $119.39 million during the same quarter last year, which suggests a positive year-over-year growth rate of 6.3%. The company is scheduled to report its next quarterly earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Acorda Therapeutics will report full-year sales of $126.87 million for the current financial year. For the next financial year, analysts expect that the business will post sales of $189.03 million per share, with estimates ranging from $104.05 million to $263.88 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Acorda Therapeutics.
Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.61 EPS for the quarter, missing analysts’ consensus estimates of $0.88 by ($0.27). The firm had revenue of $188.40 million during the quarter, compared to the consensus estimate of $171.70 million. Acorda Therapeutics had a negative net margin of 37.97% and a negative return on equity of 4.88%. The business’s revenue for the quarter was up 34.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.05 earnings per share.
A number of analysts recently issued reports on the company. Piper Jaffray Companies reaffirmed a “neutral” rating and issued a $22.00 target price on shares of Acorda Therapeutics in a research report on Tuesday, November 28th. Goldman Sachs Group raised Acorda Therapeutics from a “sell” rating to a “neutral” rating in a research report on Wednesday, February 7th. ValuEngine downgraded Acorda Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. Oppenheimer lifted their target price on Acorda Therapeutics from $18.00 to $21.00 and gave the company a “market perform” rating in a research report on Wednesday, January 31st. Finally, Leerink Swann lowered their target price on Acorda Therapeutics to $18.00 and set a “market perform” rating on the stock in a research report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $22.51.
In other Acorda Therapeutics news, insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total transaction of $226,856.50. Following the transaction, the insider now owns 33,150 shares of the company’s stock, valued at $680,569.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Lawrence sold 31,000 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $27.58, for a total value of $854,980.00. Following the transaction, the insider now directly owns 5,275 shares in the company, valued at approximately $145,484.50. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ACOR. Teachers Advisors LLC increased its position in Acorda Therapeutics by 8.0% during the second quarter. Teachers Advisors LLC now owns 78,886 shares of the biopharmaceutical company’s stock worth $1,554,000 after buying an additional 5,837 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in Acorda Therapeutics by 54.2% during the second quarter. TIAA CREF Investment Management LLC now owns 222,351 shares of the biopharmaceutical company’s stock worth $4,380,000 after buying an additional 78,133 shares during the last quarter. Nationwide Fund Advisors increased its position in Acorda Therapeutics by 7.4% during the second quarter. Nationwide Fund Advisors now owns 116,316 shares of the biopharmaceutical company’s stock worth $2,291,000 after buying an additional 7,966 shares during the last quarter. Thrivent Financial For Lutherans increased its position in Acorda Therapeutics by 8.6% during the second quarter. Thrivent Financial For Lutherans now owns 28,120 shares of the biopharmaceutical company’s stock worth $554,000 after buying an additional 2,220 shares during the last quarter. Finally, Northern Trust Corp increased its position in Acorda Therapeutics by 65.2% during the second quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock worth $17,690,000 after buying an additional 354,304 shares during the last quarter.
Acorda Therapeutics (NASDAQ ACOR) traded up $0.70 during trading hours on Friday, hitting $25.80. The company had a trading volume of 638,649 shares, compared to its average volume of 729,812. The company has a current ratio of 3.07, a quick ratio of 2.40 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $1,206.07, a P/E ratio of -5.33 and a beta of 1.63. Acorda Therapeutics has a twelve month low of $13.60 and a twelve month high of $33.00.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/19/126-87-million-in-sales-expected-for-acorda-therapeutics-inc-acor-this-quarter.html.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.